Table 4.

Serum and in vitro concentrations of CXCL8, IL−10, and fractalkine in the study groups.

	Schizophrenia (n = 60)	Control (n = 32)
CXCL8 serum [pg/mL]	13.4 ± 15.7 [9.2–17.5]	6.9 ± 4.2 [5.4–8.5]	t = 3.28 p = 0.001
IL−10 serum [pg/mL]	0.76 ± 0.97 [0.49–1.03]	0.52 ± 0.36 [0.39–0.65]	z = −1.10 p = 0.27
fractalkine serum [pg/mL]	22.8 ± 9.9 [20.0–25.5]	45.4 ± 84.5 [12.7–78.2]	z = 2.05 p = 0.041
CXCL8 non–stimulated [pg/mL]	10,107.8 ± 13,313.7 [6,438.1–13,777.5]	12,442.9 ± 14,390.4 [7,164.5–17,721.4]	z = −0.01 p = 0.99
CXCL8 PHA–stimulated [pg/mL]	1,0121.2 ± 1,0211.4 [7,306.6–12,935.8]	6,119.9 ± 5,004.3 [4,284.3–7,955.5]	t = −1.99 p = 0.05
CXCL8 ratio* [pg/mL]	3.55 ± 6.53 [1.54–5.56]	0.87 ± 0.93 [0.49–1.26]	z = −2.080 p = 0.038
IL−10 non–stimulated [pg/mL]	142.3 ± 312.6 [56.1–228.4]	179.1 ± 326.5 [59.3–298.8]	z = 0.80 p = 0.42
IL−10 PHA–stimulated [pg/mL]	910.9 ± 861.9 [673.3–1148.5]	1,034.0 ± 726.5 [767.5–1,300.5]	t = 1.05 p = 0.30
IL−10 ratio* [pg/mL]	962.68 ± 2,007.24 [344.95–1,580.43]	289.69 ± 703.62 [−0.75–580.12]	z = −1.04 p = 0.30

PHA, phytohemagglutinin.

^*PHA–stimulated to non–stimulated.

Data given as mean ± standard deviation [95% CI]. Bold values are statistically significant.